Production (Stage)
ADC Therapeutics SA
ADCT
$2.43
$0.208.97%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 17.17% | 63.86% | 5.90% | 25.30% | 21.50% |
| Total Depreciation and Amortization | -4.98% | -6.38% | -9.38% | 3.20% | 16.60% |
| Total Amortization of Deferred Charges | -62.03% | -180.26% | -37.00% | -34.62% | -39.40% |
| Total Other Non-Cash Items | -2.68% | -103.08% | 2.89% | -2.53% | 16.50% |
| Change in Net Operating Assets | -197.44% | 47.41% | 1,944.71% | -195.98% | -130.15% |
| Cash from Operations | -27.76% | 30.92% | 31.71% | 6.12% | -186.48% |
| Capital Expenditure | 50.28% | 72.48% | 67.32% | 97.52% | 47.74% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 50.28% | 72.48% | 67.32% | 97.52% | 47.74% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -23.88% | -- | -- | -- | -16.24% |
| Repurchase of Common Stock | -- | -116,200.00% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -23.88% | -111,900.00% | -351.86% | 35.01% | -16.24% |
| Foreign Exchange rate Adjustments | 474.42% | -325.66% | 346.61% | -80.33% | -148.31% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -26.75% | 26.42% | 30.34% | 78.11% | -178.80% |